Biotech & drug discovery · Neurodegeneration
Origami Therapeutics
A small San Diego company designing oral pills that strip the mutant huntingtin protein out of brain cells while leaving the normal protein alone. Still preclinical, with no registered trial and no published paper, but Ipsen bought an option on one program in January 2026.
The science of folding paper
Ask Beth Hoffman about the company name and she starts with paper. “Origami is the art of folding paper and Origami Therapeutics is the science of folding proteins.” She said that to CEOCFO Magazine in July 2020, five years after founding the company.
The rest of her answer was the whole pitch in one sentence. “We are using small molecule drugs, basically oral pills to correct and repair broken proteins.” A narrow claim and a large one at once: narrow because Origami is not editing a gene or infusing a virus, large because almost nobody has made small molecules do that job inside the brain.
What goes wrong in Huntington’s
Huntington’s disease comes from an expanded CAG repeat in the huntingtin gene. The expansion produces a long stretch of glutamines, the mutant protein folds abnormally, it gets cleaved, and the fragments poison the cell. Origami’s own NIH grant abstracts describe the rest: normal huntingtin is essential throughout the brain and body for synaptic transmission, neuroprotection, transcription and DNA repair. Strip out both forms and you remove something necessary along with something toxic.
The field has just finished a brutal demonstration of why that distinction matters. In July 2026 Roche ended development of tominersen after a Phase 2 trial performed no better than placebo, even though the drug lowered mutant huntingtin and neurofilament light. Analysts at Rodman & Renshaw blamed the mechanism: tominersen knocks down mutant and wild type huntingtin together. Meanwhile uniQure’s gene therapy AMT-130 slowed progression by 75 percent over three years in 29 evaluable patients, but it is delivered by 12 to 18 hours of intracranial surgery. Wave Life Sciences is pushing an allele-selective antisense drug toward a registrational trial, and Novartis paid PTC Therapeutics up to $2.9 billion for an oral splicing modulator.
Hoffman’s argument against that crowd is about plumbing, not biology. “Most of our competition is going after medicines that need to be delivered directly into the brain.” That means a neurosurgeon, and the drug still misses brain regions and the rest of the body, which Huntington’s also attacks. A pill, in her telling, goes everywhere.
A Vertex scientist starts over
Hoffman is not a professor who spun out a lab. She was chief of the molecular pharmacology unit at the National Institute of Mental Health, then head of neuroscience at Eli Lilly, then a scientific executive director at Amgen, then VP of discovery biology at Vertex Pharmaceuticals. At Vertex she worked on the small molecules that became the cystic fibrosis franchise: Kalydeco, Orkambi, Symdeko, Trikafta.
Those drugs work by changing the shape of a misfolded protein, and watching that gave her the thought the company is built on. “If you can do that with a small molecule, we should be able to do something similar in diseases that are caused by protein misfolding,” she told the San Diego Business Journal, adding, “I decided that no one was really working on this at all, but they should be.”
She left Vertex at the end of 2014 and founded Origami in 2015, though by her own account the wet bench work did not start until 2016. Leslie Schulze, a CPA and former finance lead at Rempex Pharmaceuticals, joined as co-founder and CFO. Hoffman picked Huntington’s first because she had worked on it for a decade and had volunteered with the Huntington’s Disease Society of America, on whose national board of trustees she now sits.
Ten years, three grants, one option
Progress was slow and deliberately so. In 2020 Hoffman told CEOCFO the company was self-funded. Origami joined Y Combinator in Winter 2022, pitched at Demo Day, and raised a seed round. Three NINDS small business grants followed, running from September 2023 to February 2027 and worth $1,109,984. The company works out of Biolabs San Diego with a headcount that has never exceeded a handful.
The capital environment did the rest of the shaping. “Venture capitalists have not been funding startups to as great a degree in the past several years as everybody would’ve hoped, including the VCs,” Hoffman told Clinical Leader. Partnering became the route. She met Ipsen at the BIO International Convention in Boston in summer 2025, and on January 30, 2026 the two announced a collaboration and option agreement on a degrader program for an undisclosed rare inherited neurodegenerative disorder. Ipsen gets an exclusive option to license it worldwide once a drug candidate is nominated; Origami keeps the research and biomarker work; Ipsen takes over IND-enabling studies and all that follows.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Federal grants | Three NINDS SBIR awards to Origami Therapeutics, Inc., PI Beth J. Hoffman: $502,931 (FY2023), $107,065 (FY2024) and $499,988 (FY2025, running to Feb 28, 2027). Total $1,109,984. All carry the R43 code, meaning Phase I. No Phase II R44 appears. | Public record |
| Ipsen agreement | Announced Jan 30, 2026 by both parties and repeated in Ipsen’s Q1 2026 sales release as a pipeline event. Exclusive option to license globally after drug candidate nomination, with an upfront payment, milestones and royalties. No figure disclosed by either side. | Public record |
| Registered clinical trials | None. No ClinicalTrials.gov registration for Origami Therapeutics as of Sep 22, 2026, and no IND has been announced. | Not found |
| Peer-reviewed papers | None found. A PubMed sweep run for this profile returned no publication by the company or on ORI-113. | Not found |
| Patents | Origami says “We’ve also secured a broad IP portfolio.” PatSnap Synapse, updated Aug 16, 2026, lists 0 medical patents for the company. Applications stay unpublished for 18 months, so the two are not necessarily inconsistent, but nothing is visible. | Claim differs from the record |
| Lead compound name | Founder interviews, the 2025 NIH award title and European Biotechnology all name ORI-113. The company’s own January 2026 Ipsen release says its lead program is ORI-003. Origami has not explained the change. | Company statements disagree |
| Preclinical data | A high throughput screen, hit-to-lead work, mechanism-of-action studies showing suppression of mutant huntingtin toxicities in patient-derived neurons, and mouse data in which the mutant protein falls while the normal one is spared. None published or externally reviewed. | Company-stated |
| Drug pipeline stage | PatSnap Synapse lists five drugs for the company, highest phase Preclinical, across nervous system and metabolic disease domains. | Data provider |
| Founding year | 2015 in the San Diego Business Journal, Tracxn and the Y Combinator listing. Longevity.Technology wrote 2016. Hoffman has said the company was founded in 2015 and began lab work in 2016, which reconciles the two. | Reports differ |
Read plainly: the validation is real but all of it sits upstream of a patient. Three federal grant panels funded the chemistry, and a listed European pharmaceutical company put its neuroscience group behind the program and said so in a quarterly sales release, which is a harder signal than a press release. What does not exist is a published dataset, a readable patent, a nominated development candidate, an IND, or a single dosed human. Hoffman said in March 2026 that safety studies were next and the clinic about 18 months away, which puts a first-in-human trial no earlier than late 2027.
What to watch
- Drug candidate nomination, the event that lets Ipsen exercise its option and triggers the milestone payments.
- Whether ORI-113 or ORI-003 is named on the first IND, and whether the Ipsen program is the Huntington’s program at all. That indication is undisclosed.
- An SBIR Phase II application. All three awards so far are Phase I, and the current one ends in February 2027.
- A first published patent application or peer-reviewed paper. Neither has appeared in ten years.
- The small round Hoffman said in March 2026 was coming, and the Series A meant to follow it.
In their words
“Origami is the art of folding paper and Origami Therapeutics is the science of folding proteins.”
Beth Hoffman, founder and CEO, CEOCFO Magazine, July 2020 · Interview
“We are using small molecule drugs, basically oral pills to correct and repair broken proteins.”
Beth Hoffman, CEOCFO Magazine, July 2020 · Interview
“Most of our competition is going after medicines that need to be delivered directly into the brain.”
Beth Hoffman, Clinical Leader, March 2026 · Interview
“In Huntington’s disease, the mutant protein actually disrupts this pathway.”
Beth Hoffman on the autophagy-lysosome system, Longevity.Technology, March 2026 · Interview
“In mouse models of Huntington’s disease, we reduce mutant protein while sparing the normal protein, which is critical.”
Beth Hoffman, Longevity.Technology, March 2026 · Company-stated data
“We are delighted to join forces with Origami whose pioneering work in developing protein degraders targeting genetic neurodegenerative diseases represents a powerful new frontier in rare neuroscience.”
Steve Glyman, SVP and Head of Neuroscience R&D, Ipsen, January 2026 · Partner release
“Venture capitalists have not been funding startups to as great a degree in the past several years as everybody would’ve hoped, including the VCs.”
Beth Hoffman, Clinical Leader, March 2026 · Interview
Related companies
Sources
- Public recordNIH RePORTER awards 1R43NS127716-01A1, 5R43NS127716-02 and 1R43NS145855-01
- IndependentOrigami and Ipsen join forces on protein degradation in neuroscience
- Public recordIpsen first quarter 2026 sales release, pipeline update
- Public recordIpsen expands pre-clinical pipeline in rare neurodegenerative diseases
- IndependentOrigami Therapeutics Inks Global Licensing Deal with Ipsen
- InterviewWhat To Look For In Rare Disease Partnerships, With Origami’s Beth Hoffman
- InterviewTargeting protein misfolding in neurodegeneration
- InterviewOrigami Therapeutics Aims to Treat Neurodegenerative Disease at its Root Cause
- InterviewBeth Hoffman, Biotech Leader Spotlight
- IndependentExit of Roche’s embattled Huntington’s drug tightens case for Wave’s more selective ASO
- Data providerPipeline, patents, funding and headcount listings
- CompanyOrigami Therapeutics Announces Global Collaboration with Ipsen
- CompanyOrigami website and Y Combinator company listing
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
